Kalaris Therapeutics (NASDAQ:KLRS) Stock Rating Upgraded by Wall Street Zen

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings cut Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, October 22nd. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.75.

Kalaris Therapeutics Stock Performance

KLRS stock opened at $2.03 on Friday. The firm has a market cap of $48.33 million, a PE ratio of -1.00 and a beta of 0.47. Kalaris Therapeutics has a one year low of $1.78 and a one year high of $11.88. The firm’s fifty day moving average is $2.95 and its 200 day moving average is $5.44.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its earnings results on Tuesday, August 11th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.02. Research analysts predict that Kalaris Therapeutics will post -1.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kalaris Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Pale Fire Capital SE acquired a new position in Kalaris Therapeutics during the second quarter worth about $161,000. Velan Capital Investment Management LP raised its position in Kalaris Therapeutics by 38.9% in the second quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock valued at $102,000 after purchasing an additional 7,000 shares during the period. Sigma Planning Corp acquired a new stake in Kalaris Therapeutics during the second quarter valued at approximately $41,000. Stonepine Capital Management LLC acquired a new stake in Kalaris Therapeutics in the 2nd quarter valued at approximately $122,597. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Kalaris Therapeutics during the 2nd quarter worth $407,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Kalaris Therapeutics Company Profile

Kalaris Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases, a group of eye conditions that can lead to vision loss. The company’s research is aimed at addressing diseases in which abnormal blood-vessel growth or leakage damages the retina.

Kalaris Therapeutics’ lead investigational product candidate is KAL-101, an experimental therapy being developed for retinal diseases. The company is advancing KAL-101 through clinical development and evaluating its potential to provide a treatment option for patients with conditions requiring ongoing management of retinal vascular abnormalities.

The company’s activities primarily center on research, clinical development, and the potential commercialization of ophthalmic medicines.